To highlight the critical importance of distinguishing between brain metastasis and primary brain tumors in lung cancer patients, particularly in the context of ALK-positive lung adenocarcinoma, as this distinction significantly impacts treatment strategies and patient outcomes.
Key Findings:
The patient was treated for presumed brain metastasis with lorlatinib and stereotactic radiotherapy, which may have delayed appropriate treatment for glioblastoma.
Pathological examination confirmed the lesion as primary glioblastoma, indicating a metachronous double primary cancer, which is a rare occurrence.
The patient experienced progressive neurological symptoms and died 10 months after glioblastoma diagnosis, underscoring the need for accurate diagnosis.
Interpretation:
This case underscores the need for heightened clinical vigilance in considering second primary cancers in patients with a history of malignancies, especially when treatment responses are atypical, as misdiagnosis can lead to significant delays in appropriate care.
Limitations:
The rarity of double primary cancers makes it difficult to generalize findings, potentially leading to under-recognition in clinical practice.
Limited literature on similar cases may hinder comprehensive understanding and awareness among clinicians.
Conclusion:
Timely pathological confirmation and a multidisciplinary approach are essential to avoid diagnostic delays and improve treatment outcomes in patients with new intracranial lesions, particularly in complex cases like this.
